GSK to sell 240 million shares in spin-off firm Haleon

This post was originally published on this site

GSK, which is the second largest shareholder of London-listed Haleon, said it will sell the stake via a placing of ordinary shares. The offer price will be determined through an accelerated bookbuild offering process, which will commence immediately.

Haleon’s shares closed marginally up 0.9% at 342.85 pence on May 11.